C12Y203/01001

HIGH YIELD ROUTE FOR THE PRODUCTION OF COMPOUNDS FROM RENEWABLE SOURCES
20220389433 · 2022-12-08 ·

Provided herein are methods, compositions, and non-naturally occurring microbial organism for preparing compounds such as α-butanol, butyric acid, succinic acid, 1,4-butanediol, 1-pentanol, pentanoic acid, glutaric acid, 1,5-pentanediol, 1-hexanol, hexanoic acid, adipic acid, 1,6-hexanediol, 6-hydroxy hexanoic acid, ε-Caprolactone, 6-amino-hexanoic acid, ε-Caprolactam, hexamethylenediamine, linear fatty acids and linear fatty alcohols that are between 7-25 carbons long, linear alkanes and linear α-alkenes that are between 6-24 carbons long, sebacic acid and dodecanedioic acid comprising: a) converting a C.sub.N aldehyde and pyruvate to a C.sub.N+3 β-hydroxyketone intermediate through an aldol addition; and b) converting the C.sub.N+3 β-hydroxyketone intermediate to the compounds through enzymatic steps, or a combination of enzymatic and chemical steps.

METHODS FOR PREPARING N-ACETYL-L-METHIONINE

The present disclosure relates to a polypeptide having an acyltransferase activity or a microorganism including the same; a composition for preparing N-acetyl-L-methionine, the composition including the polypeptide or microorganism; and a method of preparing N-acetyl-L-methionine using the polypeptide or microorganism. Further, the present disclosure relates to a polynucleotide encoding the polypeptide and an expression vector including the polynucleotide. Since the microorganism including a novel acyltransferase according to the present disclosure has enhanced acyltransferase activity, this microorganism can be efficiently used for producing N-acetyl-L-methionine by acetylating L-methionine.

Microorganism for producing ornithine and process for producing ornithine using them

Disclosed is a modified microorganism producing putrescine or ornithine, and a method for producing putrescine or ornithine using the same.

TROPANE ALKALOID (TA) PRODUCING NON-PLANT HOST CELLS, AND METHODS OF MAKING AND USING THE SAME
20220170026 · 2022-06-02 ·

Provided herein, among other things, is an engineered non-plant cell that produces a tropane alkaloid product, a precursor of a tropane alkaloid product, or a derivative of a tropane alkaloid product. A method for producing a tropane alkaloid, a precursor of a tropane alkaloid product, or a derivative of a tropane alkaloid product that makes use of the cell is also described.

Transaminase mutant and use thereof

Disclosed are transaminase mutants and use thereof. The amino acid sequence of the transaminase mutant is obtained by the mutation of the amino acid sequence as shown in SEQ ID NO: 1, and the mutation at least comprises one of the following mutation sites: the 19-th site, the 41-th site, the 43-th site, the 72-th site, the 76-th site, the 92-th site, the 107-th site, the 125-th site, the 132-th site, the 226-th site, the 292-th site, the 295-th site, the 308-th site, and the 332-th site; and the 19-th site is mutated into a serine, the 41-th site is mutated into a serine, the 43-th site is mutated into an asparagine, a glycine in the 72-th site is mutated into a leucine, etc.; or the amino acid sequence of the transaminase mutant has the mutation sites in the mutanted amino acid sequence, and has more than 80% homology to the mutanted amino acid sequence.

Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them

Disclosed is a modified microorganism producing putrescine or ornithine, and a method for producing putrescine or ornithine using the same.

MICROORGANISM FOR PRODUCING PUTRESCINE AND PROCESS FOR PRODUCING PUTRESCINE BY USING SAME

The present invention relates to a microorganism for producing putrescine and a method for producing putrescine by using same.

BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.

Bacteria engineered to treat diseases associated with hyperammonemia

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.